Valuation Charles River Laboratories International, Inc.

Stocks

Market Closed - NYSE 04:00:02 2026-10-02 pm EDT			5-day change	1st Jan Change
290.19 ^USD	+1.17%		-0.90%	+45.47%

Sep. 30	UBS Upgrades Charles River Laboratories International to Buy From Neutral, Adjusts Price Target to $357 From $175	MT
Sep. 29	PMGC Unit Working With Charles River Laboratories for Muscle Health Probiotic Testing	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	18,941	11,138	12,252	9,520	10,023	13,853	-	-
Change	-	-41.2%	10%	-22.3%	5.29%	38.21%	-	-
Enterprise Value (EV) ¹	21,366	13,616	14,622	11,565	11,946	16,006	15,559	15,183
Change	-	-36.28%	7.39%	-20.91%	3.29%	33.99%	-2.8%	-2.41%
P/E	49.4x	23.1x	25.9x	931x	-70x	77.1x	31x	27.6x
PBR	7.45x	3.75x	3.41x	2.75x	3.17x	4.62x	3.97x	3.53x
PEG	-	0.9x	-9.44x	-9.5x	0x	-0x	0x	2.3x
Capitalization / Revenue	5.35x	2.8x	2.97x	2.35x	2.5x	3.54x	3.46x	3.27x
EV / Revenue	6.04x	3.42x	3.54x	2.86x	2.98x	4.09x	3.88x	3.59x
EV / EBITDA	24.3x	13.7x	14.4x	11.6x	12.3x	15.7x	14x	12.7x
EV / EBIT	28.8x	16.3x	17.4x	14.3x	15x	19.5x	16.9x	14.9x
EV / FCF	40.2x	46.2x	40x	23.1x	23x	50.3x	25.3x	31.9x
FCF Yield	2.49%	2.17%	2.5%	4.34%	4.34%	1.99%	3.95%	3.13%
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	7.6	9.48	9.22	0.2	-2.91	3.763	9.362	10.5
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	3,540	3,976	4,129	4,050	4,015	3,918	4,006	4,234
EBITDA ¹	879.5	990.9	1,013	996.1	971.5	1,020	1,111	1,193
EBIT ¹	742.1	834	838.8	805.9	793.9	821.7	919	1,017
Net income ¹	391	486.2	474.6	10.3	-144.3	164.1	431.1	475.7
Net Debt ¹	2,425	2,477	2,370	2,046	1,923	2,153	1,705	1,330
Reference price ²	375.34	218.92	238.84	186.16	203.66	290.19	290.19	290.19
Nbr of stocks (in thousands)	50,464	50,879	51,297	51,136	49,215	47,739	-	-
Announcement Date	2/16/22	2/22/23	2/14/24	2/19/25	2/18/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	77.11x	4.09x	15.7x	-.--%	13.85B
WUXI APPTEC CO., LTD.	21.73x	7.71x	15.48x	1.37%	74.16B
ARGENX SE	29.82x	8.57x	26.7x	0.04%	57.39B
LONZA GROUP AG	32.98x	5.93x	17.77x	0.98%	47.64B
REVOLUTION MEDICINES, INC.	-21.31x	230.81x	-22.97x	-.--%	44.29B
IQVIA HOLDINGS INC.	33.26x	3.23x	13.97x	-.--%	42.5B
BEONE MEDICINES AG	46.77x	5.41x	29.66x	-.--%	40.71B
CELLTRION, INC.	27.63x	7.93x	20.48x	0.41%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	32.99x	7.05x	18.3x	-.--%	28.53B
BIONTECH SE	-15.1x	5.68x	-7.14x	-.--%	24.34B
Average	26.59x	28.64x	12.79x	0.28%	40.44B
Weighted average by Cap.	24.15x	31.08x	13.63x	0.4%